|
[1] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[2]WONG GL,WONG VW,CHOI PC,et al.Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B[J].Gut,2009,58(1):111-117.
|
|
[3]HA M,XIA W,TANG D,et al.Hepatitis B e antigen-positive and high levels of alanine aminotransferase are associated with prevalence of metabolic syndrome in chronic HBV patients[J].Obes Res Clin Pract,2015.[Epub ahead of print]
|
|
[4]LI WC,LEE YY,CHEN IC,et al.Association between the hepatitis B and C viruses and metabolic diseases in patients stratified by age[J].Liver Int,2013,33(8):1194-1202.
|
|
[5]CHUNG TH,KIM MC,KIM CS.Association between hepatitis B surface antigen seropositivity and metabolic syndrome[J].Korean J Fam Med,2014,35(35):81-89.
|
|
[6]JINJUVADIA R,LIANGPUNSAKUL S.Association between metabolic syndrome and its individual components with viral hepatitis B[J].Am J Med Sci,2014,347(1):23-27.
|
|
[7]HUANG CY,LU CW,LIU YL,et al.Relationship between chronic hepatitis B and metabolic syndrome:a structural equation modeling approach[J].Obesity,2016,24(2):483-489.
|
|
[8]JARCUSKA P,JANICKO M,KRUZLIAK P,et al.Hepatitis B virus infection in patients with metabolic syndrome:a complicated relationship.Results of a population based study[J].Eur J Intern Med,2014,25(3):286-291.
|
|
[9]ZHOU Y,CUI Y,DENG H,et al.Association between hepatitis B virus infection and metabolic syndrome:a retrospective cohort study in Shanghai,China[J].BMC Public Health,2014,14(1):516.
|
|
[10]KATOONIZADEH A,GHOROGHI S,SHARAFKHAH M,et al.Chronic hepatitis B infection is not associated with increased risk of vascular mortality while having an association with metabolic syndrome[J].J Med Virol,2016,88(7):1230-1237.
|
|
[11]TARGHER G,BERTOLINI L,PADOVANI R,et al.Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C[J].J Hepatol,2007,46(6):1126-1132.
|
|
[12]PAPATHEODORIDIS GV,MANESIS EK,MANOLAKOPOULOS S,et al.Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?[J].Hepatology,2008,48(5):1451-1459.
|
|
[13]CHENG YL,WANG YJ,KAO WY,et al.Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up[J].PLoS One,2013,8(8):903-906.
|
|
[14]WONG VW,WONG GL,CHU WC,et al.Hepatitis B virus infection and fatty liver in the general population[J].J Heptol,2012,56(3):533-540.
|
|
[15]MACHADO MV,OLIVEIRA AG,CORTEZ-PINTO H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients[J].J Gastroenterol Hepatol,2011,26(9):1361-1367.
|
|
[16]WU YL,PENG XE,ZHU YB,et al.Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein[J].J Virol,2015,90(4):1729-1740.
|
|
[17]TURATI F,TALAMINI R,PELUCCHI C,et al.Metabolic syndrome and hepatocellular carcinoma risk[J].Br J Cancer,2013,108(1):222-228.
|
|
[18]MENAA,PEDREIRA JD,CASTRO A,et al.Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers[J].J Gastroenterol Hepatol,2014,29(1):173-178.
|
|
[19]ZHANG F,ZHANG Z,KONG D,et al.Tetramethyl pyrazine reduces glucose and insulin—induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated P13K/AKT and ERK pathways[J].Mol Cell Endocrinol,2014,382(1):197-204.
|
|
[20]ZHANG RN,PAN Q,ZHANG Z,et al.Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by Toll-Like receptor 4-mediated innate immune response[J].Hepat Mon,2015,15(5):e27909.
|
|
[21]Expert Committee on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease.Recommendation for the standardization of diagnosis and treatment of fatty liver disease[J].J Clin Hepatol,2013,29(9):207-209.(in Chinese)中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].临床肝胆病杂志,2013,29(9):207-209.
|
|
[22]MALIK R,AFDHAL N.Stiffness and impedance:the new liver biomarkers[J].Clin Gastroenterol Hepatol,2007,5(10):1144-1146.
|
|
[23]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[24]CAVIGLIA GP,ABATE ML,PELLICANO R,et al.Chronic hepatitis B therapy:available drugs and treatment guidelines[J].Minerva Gastroenterol Dietol,2015,61(2):61-70.
|
|
[25]VALLET-PICHARD A,POL S.Hepatitis B virus treatment beyond the guidelines:special populations and consideration of treatment withdrawal[J].Therap Adv Gastroenterol,2014,7(4):148-155.
|
|
[26]NEWSOME PN,ALLISON ME,ANDREWS PA,et al.Guidelines for liver transplantation for patients with non-alcoholic steato hepatitis[J].Gut,2012,61(4):484-500.
|
|
[27]GONG L,LIU J,WANG J,et al.Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B[J].Transplant Proc,2015,47(10):2886-2891.
|
|
[28]SHI JP,FAN JG,WU R,et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injure in Chinese patients with chronic hepatitis B[J].J Gastroenterol Hepatol,2008,23(9):1419-1425.
|
DownLoad: